Arthrosi Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arthrosi Therapeutics, Inc. - overview
Established
2018
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Founded in 2018 by its CEO Litain Yeh, and COO Shunqi Yan and based in California, US, Arthrosi Therapeutics operates as a biotechnology drugs developer. In June 2025, Arthrosi Therapeutics, Inc. raised USD 60. 87 million in series E funding led by Prime Eight Capital, with participation from CR Biotech, HighLight Capital, HM Venture Partners, and Reliant Technologies Inc.
The series E funding values Arthrosi Therapeutics, Inc. at USD 217. 11 million post-money. The company provides biotechnology drugs for gout patients and chronic kidney disease.
The company develops the first generation of urate inhibitor treatment for gout. The company's product includes AR882, which is a novel uric acid excretory agent in clinical development for the treatment of hyperuricemia in patients with gout, including those with chronic refractory gout. The company plans to use the funding to finish the crucial development of Pozdeutinurad, a medication used to treat tophaceous and gout.
Current Investors
HEDA Ventures, Changrong Capital, Fenghe Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.arthrosi.com
Verticals
HealthTech
Company Stage
Series E
Total Amount Raised
Subscriber access only
Arthrosi Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.